Immuron Ltd ADR (IMRN)vsModerna Inc (MRNA)
IMRN
Immuron Ltd ADR
$1.45
-11.04%
HEALTHCARE · Cap: $9.44M
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 28784% more annual revenue ($2.23B vs $7.71M). IMRN leads profitability with a -49.8% profit margin vs -141.4%. IMRN earns a higher WallStSmart Score of 30/100 (F).
IMRN
Avoid30
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IMRN.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -65.1% — below average capital efficiency
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : IMRN
The strongest argument for IMRN centers on Price/Book.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : IMRN
The primary concerns for IMRN are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
IMRN is growing revenue faster at 7.2% — sustainability is the question.
IMRN generates stronger free cash flow (-767,378), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
IMRN scores higher overall (30/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Immuron Ltd ADR
HEALTHCARE · BIOTECHNOLOGY · USA
Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immunomodulated diseases in Australia, the United States and internationally. The company is headquartered in Carlton, Australia.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?